富国恒生港股通创新药及医疗保健ETF发起式联接C(020111)财务指标
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 本期已实现收益 |
126,679,720.04 |
34,643,209.76 |
-321,282.67 |
-503,120.54 |
| 本期利润 |
103,541,711.19 |
100,764,850.72 |
-772,154.28 |
-1,490,958.51 |
| 加权平均基金份额本期利润 |
0.34 |
0.46 |
-0.09 |
-0.27 |
| 本期加权平均净值利润率(%) |
24.43 |
41.78 |
-10.98 |
-33.21 |
| 本期基金份额净值增长率(%) |
52.06 |
45.57 |
-14.73 |
-25.27 |
| 期末可供分配利润 |
113,703,512.07 |
14,228,315.45 |
-1,817,564.03 |
-2,177,105.19 |
| 期末可供分配基金份额利润 |
0.28 |
0.04 |
-0.13 |
-0.24 |
| 期末基金资产净值 |
537,306,716.41 |
480,459,300.73 |
12,011,283.09 |
6,943,436.31 |
| 期末基金份额净值 |
1.32 |
1.26 |
0.87 |
0.76 |
| 基金份额累计净值增长率(%) |
32.08 |
26.44 |
-13.14 |
-23.87 |
微信公众号
证券之星APP
基本资料
